scholarly journals Time Taken for Symptom Recognition, First Consultation, Diagnosis and First Definitive Treatment and Its Associated Factors among Women with Breast Cancer

2021 ◽  
Vol 22 (11) ◽  
pp. 3623-3631
Author(s):  
Bachok Norsa’adah ◽  
Krishna Rampal ◽  
Rahmah Mohd Amin
Keyword(s):  
Breast Cancer ◽  
Associated Factors ◽  
Definitive Treatment ◽  
Symptom Recognition

scholarly journals Frailty in Older Breast Cancer Survivors: Age, Prevalence, and Associated Factors

2013 ◽  
Vol 40 (3) ◽  
pp. E126-E134 ◽  
Author(s):  
Jill A. Bennett ◽  
Kerri M. Winters-Stone ◽  
Jessica Dobek ◽  
Lillian M. Nail
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Associated Factors ◽  
Breast Cancer Survivors

Application of RSClin to guide treatment recommendations for premenopausal patients with early-stage hormone-positive breast cancer and intermediate risk oncotype recurrence scores.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12511-e12511
Author(s):  
Brittney Shulman Zimmerman ◽  
Shana Berwick ◽  
Alaina J Kessler ◽  
Danielle Seidman ◽  
Sara Malin Hovstadius ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Medical Center ◽  
Academic Medical Center ◽  
Recurrence Score ◽  
Treatment Recommendations ◽  
Definitive Treatment ◽  
Treatment Recommendation ◽  
Intermediate Risk ◽  
Premenopausal Patients

e12511 Background: The RSClin model, which incorporates the Oncotype Recurrence Score (RS) and clinicopathologic features, was recently developed to further tailor prognosis and prediction of chemotherapy benefit for patients with early-stage hormone positive (HR+) breast cancer (BC) (Sparano et al, 2020). The RSClin calculator is available online to assist treatment planning for situations where chemotherapy benefit is uncertain. Covariates include Oncotype RS, tumor grade, tumor size and patient age. The risk calculator generates a 10-year distant recurrence risk and absolute chemotherapy benefit. This tool may be especially helpful to determine treatment management for premenopausal patients with early-stage HR+ BC with intermediate risk (IR) Oncotype RS (16-25). We retrospectively applied RSClin to this patient population to determine if it would have changed treatment recommendations. Methods: We identified premenopausal women with node-negative early-stage BC with IR RS (16-25) within our large Oncotype database. Using the RSClin model, we selected >5% absolute chemotherapy benefit as a reasonable cutoff to recommend chemotherapy. We compared the treatment recommendation based on RSClin with the treatment previously recommended by breast oncologists at our large academic medical center in New York City. Results: There were 86 patients who met criteria with a median age of 46 years. Of these, 26 patients (30%) were recommended chemotherapy plus endocrine therapy (ET) and 60 (70%) were recommended ET alone. After applying the RSClin model (data available for 83/86 patients), 19 (23%) would have resulted in a change in treatment recommendation and 64 (77%) would have remained unchanged. Overall, 8 (10%) would have withheld chemotherapy when it was previously offered and 11 (13%) would have recommended chemotherapy when it was previously excluded. There were 8 (9%) secondary invasive breast events in this population, with 2 (2%) being ipsilateral, 3 (3%) being contralateral and 3 (3%) metastatic at a median follow up of 46.9 months. Conclusions: The RSClin model would have changed management of premenopausal patients with IR RS in 23% of patients. This model, although not yet prospectively validated, may help individualize therapy for patients with less definitive treatment plans. Using RSClin, we can aim to minimize recurrence rates and avoid unnecessary chemotherapy in selected patients. This model is easy to apply and will have important clinical utility moving forward.

scholarly journals Body Image, Life Satisfaction and Associated Factors Among Swedish Women with Breast Cancer After Mastectomy

2021 ◽  
Author(s):  
Nitikorn Phoosuwan ◽  
Pranee C. Lundberg
Keyword(s):  
Breast Cancer ◽  
Body Image ◽  
Life Satisfaction ◽  
Associated Factors ◽  
Treatment Options ◽  
Body Image Dissatisfaction ◽  
Physical Symptoms ◽  
Demographic Characteristics ◽  
Sources Of Information

Abstract Background Women having undergone mastectomy due to breast cancer have experiences which are very much individual and contextual. In order to facilitate efforts to understand the women and improve their quality of life, the aim of this study was to investigate body image, life satisfaction and associated factors among Swedish women with breast cancer after mastectomy.Methods After mastectomy, four hundred and eighty-one Swedish women with breast cancer were enrolled in a descriptive cross-sectional study. Each participant completed a questionnaire comprising socio-demographic characteristics, sources of information, body image and life satisfaction. Multiple linear regression analyses were used to estimate relationships between socio-demographic characteristics, information support, sources of information, treatment variables, and outcome variables such as body image and life satisfaction.Results Body image was associated with all dimensions of life satisfaction. Lower age, underlying disease, chemotherapy and breast reconstruction increased body image dissatisfaction, while treatment options were factors associated with life satisfaction. Sources of information was a factor that increased life satisfaction in the dimensions of physical symptoms, sickness impact and quality of close friend relationship.Conclusion The findings highlight that some socio-demographic characteristics, treatment options and sources of information were associated with body image dissatisfaction and life dissatisfaction among the women with breast cancer after mastectomy. This can increase healthcare professionals’ understanding of women with breast cancer after treatment. They should provide effective information, focus attention on the women’s needs, and prepare intervention programs that make the women cope with their life situations during follow-up care.

scholarly journals Surgical site infection after breast cancer surgery at 30 days and associated factors

Infectio ◽  
2017 ◽  
Vol 21 (2) ◽  
Author(s):  
Joana-Cristina Gil-Londoño ◽  
Jorge-Alberto Nagles-Pelaez ◽  
Wilmar-Arley Maya-Salazar ◽  
Jorge Madrid ◽  
Maria-Angelica Maya-Restrepo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Surgical Site Infection ◽  
Associated Factors ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Cáncer De Mama ◽  
Site Infection ◽  
Kaplan Meier ◽  
Factores De Riesgo ◽  
Las Mujeres

Antecedentes: La incidencia de infección del sitio operatorio (ISO) en cirugía de mama ha sido mayor de lo esperado, considerando este como un procedimiento quirúrgico limpio. Pocos estudios han reportado una incidencia menor del 5,0% y la mayoría de publicaciones la ubican entre 10,2 y 30,0%. Objetivo: Estimar la incidencia, los factores asociados y el intervalo libre de infección a 30 días, en las mujeres que se sometieron a cirugía oncológica y reconstructiva de mama. Métodos: Estudio de cohorte prospectivo en mujeres con cáncer de mama, que se sometieron a cirugía de mama conservadora o radical en un centro médico de referencia de Medellín, Colombia. Los resultados fueron infección del sitio operatorio y tiempo al evento. El análisis de supervivencia libre de infección se realizó con el método de Kaplan Meier y el modelo multivariado de riesgos proporcionales de Cox. Resultados: Seguimiento a 308 procedimientos quirúrgicos oncológicos de mama consecutivos; 161 (52,3%) fueron cuadrantectomías y 147 (47,7%) mastectomías, con una incidencia de ISO de 16,2% (50 casos). Los factores de riesgo asociados fueron: seroma-hematoma 79 (25,6%), HR 2,7 (IC 95%: 1,5; 4,9) y la presencia de dispositivos de drenaje, HR 5,6 (IC 95% 2,2; 14,3). El tiempo medio para el desarrollo de SSI fue de 16 días. Conclusión: Nuestro estudio mostró que la presencia de seroma hematoma posoperatorios y el uso extendido de dispositivos de drenaje fueron factores independientes para la presentación de infección del sitio operatorio en cirugía oncológica de mama.

Sign in / Sign up

Export Citation Format

Share Document